Drug Trial Radar · NCT07497087
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
448
Planned (sponsor's estimate)
Start
Jul 27, 2026
Primary completion
Feb 26, 2030
Study completion Mar 17, 2030
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Mar 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Nerandomilast is being developed to help people with systemic sclerosis by potentially improving symptoms and slowing disease progression. This study is open to adults who are at least 18 years old and have systemic sclerosis (SSc). People can join the study if they have limited or diffuse cutaneous SSc with disease onset within 7 years of the first non-Raynaud's symptom. The purpose of this study is to find out whether a medicine called nerandomilast helps people with systemic sclerosis. This study also aims to find out how well nerandomilast is tolerated in people with systemic sclerosis. Participants are put into 2 groups randomly, which means by chance. One group takes nerandomilast tablets and the other group takes placebo tablets. Placebo tablets look like nerandomilast tablets but do not contain any medicine. Participants take the tablets twice a day. Participants are in the study for 1 to about 4 years. During this time, they visit the study site regularly and get phone calls from the site staff. During study visits participants regularly have blood samples taken and doctors check changes in skin thickening, lung function, and internal organs, overall health and the safety and tolerability of study treatment in people with SSc. The results are compared between the groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.
Conditions
- Systemic Sclerosis
Interventions
Placebo matching nerandomilast formulation 1Drug
Film-coated tablets
Placebo matching nerandomilast formulation 2Drug
Film-coated tablets
Nerandomilast formulation 1Drug
Film-coated tablets
Nerandomilast formulation 2Drug
Film-coated tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to the first occurrence of disease progression or all-cause deathTime frame: up to 4 years
Locations
248 sites in 45 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama · Not yet recruiting
Banner - University Medicine Rheumatology Clinic
Phoenix, Arizona · Not yet recruiting
Arizona Arthritis and Rheumatology Associates - Paradise Valley
Scottsdale, Arizona · Not yet recruiting
University of California Los Angeles
Los Angeles, California · Not yet recruiting
Paradigm Clinical Research - San Diego
San Diego, California · Recruiting
Stanford University School of Medicine
Stanford, California · Not yet recruiting
Medvin Clinical Research-Whittier-69033
Whittier, California · Recruiting
University of Colorado Denver
Aurora, Colorado · Not yet recruiting
Georgetown University
Washington D.C., District of Columbia · Not yet recruiting
Millennium Research - Ormond Beach
Ormond Beach, Florida · Recruiting
Integral Rheumatology and Immunology Specialist
Plantation, Florida · Not yet recruiting
BioResearch Partner - South Miami
South Miami, Florida · Recruiting
Northwestern University
Chicago, Illinois · Not yet recruiting
The University of Chicago Medical Center
Chicago, Illinois · Not yet recruiting
DelRicht Research-New Orleans-64100
New Orleans, Louisiana · Recruiting
Johns Hopkins Hospital
Baltimore, Maryland · Not yet recruiting
Massachusetts General Hospital
Boston, Massachusetts · Not yet recruiting
University of Michigan
Ann Arbor, Michigan · Not yet recruiting
Clinical Research Institute of Michigan, LLC - St. Clair Shores
Saint Clair Shores, Michigan · Recruiting
M Health Fairview University of Minnesota Medical Center
Minneapolis, Minnesota · Not yet recruiting
Rutgers Robert Wood Johnson Medical School
New Brunswick, New Jersey · Recruiting
Hospital for Special Surgery
New York, New York · Not yet recruiting
Icahn School of Medicine at Mount Sinai
New York, New York · Not yet recruiting
Columbia University Medical Center-New York Presbyterian Hospital
New York, New York · Not yet recruiting
University of Pennsylvania
Philadelphia, Pennsylvania · Not yet recruiting
Thomas Jefferson University
Philadelphia, Pennsylvania · Recruiting
West Tennessee Research Institute
Jackson, Tennessee · Recruiting
Tekton Research, Inc - West Gate Boulevard
Austin, Texas · Recruiting
Arthritis & Rheumatology Institute - Frisco
Frisco, Texas · Recruiting
The University of Texas Health Science Center at Houston
Houston, Texas · Not yet recruiting
Centro Medico Reumatologico - OMI
CABA, Argentina · Recruiting
Mautalen- Salud e Investigacion
CABA, Argentina · Recruiting
Instituto de Investigacion Clinica TyT
CABA, Argentina · Recruiting
Sanatorio Maipu
Maipu, Argentina · Recruiting
Instituto de Investigaciones Clinicas de Quilmes
Quilmes, Argentina · Recruiting
Sanatorio de la Mujer
Rosario, Argentina · Recruiting
Westmead Hospital
Westmead, New South Wales, Australia · Not yet recruiting
Royal Adelaide Hospital
Adelaide, South Australia, Australia · Not yet recruiting
St Vincent's Hospital Melbourne
Fitzroy, Victoria, Australia · Not yet recruiting
Medizinische Universitaet Innsbruck
Innsbruck, Austria · Not yet recruiting
Showing 40 of 248 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.